Cargando…
Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab
BACKGROUND: We hypothesized that elevations of plasma Oncostatin M (OSM) would be associated with infliximab nonresponse. METHODS: Plasma OSM was measured in Crohn disease patients pre-infliximab with biochemical response (>50% reduction in fecal calprotectin) as the primary outcome. RESULTS: The...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798793/ https://www.ncbi.nlm.nih.gov/pubmed/31667468 http://dx.doi.org/10.1093/crocol/otz026 |
Sumario: | BACKGROUND: We hypothesized that elevations of plasma Oncostatin M (OSM) would be associated with infliximab nonresponse. METHODS: Plasma OSM was measured in Crohn disease patients pre-infliximab with biochemical response (>50% reduction in fecal calprotectin) as the primary outcome. RESULTS: The median OSM in biochemical responders was 86 (69–148) pg/mL compared with 166 (74–1766) pg/mL in nonresponders (P = 0.03). Plasma OSM > 143.5 pg/mL was 71% sensitive and 78% specific for biochemical nonresponse (area under the curve 0.71). Early biochemical nonremission was also associated with an elevated neutrophil CD64 expression (odds ratio 8.9, P = 0.011). CONCLUSIONS: Elevated preinfliximab plasma OSM and nCD64 surface expression were both associated with poor biochemical outcomes. |
---|